Cel Sci Corporation (CVM)

[GD]

FWIW, my reading tea leaf from NWBO management behavior tells me
the new changed primary OS comparing historical control is SS,
the important secondary endpoints are not, but the most troubling
are the OS from subgroups with MGMT methylation status and IDH
mutation status not SS comparing the original treat arm vs placebo
arm, if this is the case which I believe is, otherwise, no need for
NWBO to delay for so long to PR TLD, NWBO may go down less than 50
cents, IMO.